Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Transplantation outcomes in patients with Down syndrome-associated acute lymphoblastic leukaemia: Implications for treatment intensity and the use of novel therapies.

British journal of haematology·2026
Same author

Idiopathic Pulmonary Hemosiderosis Complicated by Direct Antiglobulin Test-negative Autoimmune Hemolytic Anemia.

Journal of pediatric hematology/oncology·2025
Same author

Outcome of hematopoietic stem cell transplantation in pediatric patients with acute lymphoblastic leukemia not in remission enrolled in JACLS ALL-02.

International journal of hematology·2023
Same author

Prednisolone poor response is not an indication for HSCT in pediatric B-cell precursor acute lymphoblastic leukemia in first remission: results from JACLS ALL-02 study.

International journal of hematology·2021
Same author

Leukemic cells expressing NCOR1-LYN are sensitive to dasatinib in vivo in a patient-derived xenograft mouse model.

Leukemia·2020
Same author

Validation of the United Kingdom copy-number alteration classifier in 3239 children with B-cell precursor ALL.

Blood advances·2019

Related Experiment Video

Updated: Jun 11, 2025

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.0K

[Progress in therapy with L-asparaginase].

Mio Yano1

  • 1Department of Pediatrics, Kyoto City Hospital.

[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology
|October 2, 2024
PubMed
Summary
This summary is machine-generated.

L-asparaginase is crucial for treating acute lymphocytic leukemia/lymphoblastic lymphoma across all ages. Ensuring treatment completion through managing side effects and therapeutic drug monitoring is vital for better survival outcomes.

Keywords:
Acute lymphoblastic leukemiaL-asparaginaseLymphoblastic lymphomaNewly approved drugs

More Related Videos

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
09:02

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

11.9K
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.1K

Related Experiment Videos

Last Updated: Jun 11, 2025

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.0K
Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
09:02

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

11.9K
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.1K

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • L-asparaginase is a critical chemotherapeutic agent for acute lymphocytic leukemia/lymphoblastic lymphoma.
  • Treatment completion is essential for improved patient survival outcomes.

Purpose of the Study:

  • To review advances in L-asparaginase therapy.
  • To outline current and future challenges in maximizing L-asparaginase efficacy and safety.

Main Methods:

  • Literature review of L-asparaginase therapy.
  • Analysis of strategies for managing adverse events and optimizing administration.

Main Results:

  • Effective management of hypersensitivity reactions and other adverse events is key.
  • Therapeutic drug monitoring aids in optimizing L-asparaginase administration.
  • New L-asparaginase preparations in Japan offer potential for improved treatment.

Conclusions:

  • Maximizing therapeutic efficacy requires addressing administration challenges and adverse events.
  • Continued research and strategic use of L-asparaginase are essential for improving leukemia treatment.